Collaboration Spotlight: Advancing Leptomeningeal Metastases Research

Last week, the leadership teams from Plus Therapeutics and CNSide Diagnostics came together onsite at #SNOASCO2025 in Baltimore, Maryland.

Their jointly sponsored symposium on leptomeningeal metastases (LM) was the most attended ISS symposium of the event, highlighting growing interest in cutting-edge approaches to CNS metastases detection and management.

Key Achievements at the Conference

• FORESEE Poster Award: The CNSide and Dr. Priya Kumthekar poster on longitudinal detection and monitoring of LM received first place, underscoring its clinical impact.
• Engagement with KOLs & Advocacy Groups: Leadership teams held multiple meetings with key opinion leaders and patient advocacy groups, fostering collaborations for research and clinical care.
• Symposium Recording Available: For those who missed it, you can request a recording of the symposium here.

About CNSide Diagnostics

CNSide Diagnostics is dedicated to transforming CNS cancer care through its CSF assay platform, enabling sensitive detection, longitudinal monitoring, and personalized treatment strategies for patients with leptomeningeal metastases.

• Explore our CSF assay platform
• Review our research publications
• Learn more about our mission and leadership

#PlusTherapeutics #CNSide #SNOASCO2025 #LeptomeningealMetastases #LM #CNSCancer #NeuroOncology #CancerDiagnostics #PrecisionMedicine #BrainCancer